Moxapride citrate and morpholine, both belong to the regulation of gastrointestinal power drugs, the two main action site, pharmacological mechanism, adverse reactions are different. 1, action site: Moxapride citrate is mainly the regulation of the gastrointestinal tract power drugs, morpholine mainly regulates the stomach power drugs; 2, pharmacological mechanism: Moxapride citrate can promote the release of acetylcholine, stimulate the gastrointestinal tract to play a pro-dynamic role, thereby improving the symptoms of functional dyspepsia patients such as heartburn, belching, early satiety, epigastric distension, and does not affect the secretion of gastric acid. Thus, it can improve the symptoms of gastrointestinal tract in patients with functional dyspepsia, such as heartburn, belching, early satiety and epigastric distension, and does not affect the secretion of gastric acid. The main component of morpholine is an agonist of dopamine receptors, which can be used to treat symptoms of indigestion caused by delayed gastric emptying and esophageal reflux, as well as nausea and vomiting caused by radiotherapy, infection, diet, etc. It can also inhibit the secretion of gastric acid; 3, adverse reactions: the adverse reactions of mosapride citrate mainly include diarrhea, abdominal pain, dry mouth, rash, dizziness and other symptoms, occasionally see eosinophils The phenomenon of increased eosinophils and elevated glutamate transaminase. The poor permeability of morpholine to the blood-cerebrospinal fluid barrier can cause dry mouth, headache, insomnia, hypersensitivity, stomatitis, conjunctivitis, and even lead to adverse reactions such as increased prolactin levels, breast overflow, and feminization of male breasts. Also morpholine has an effect in the extrapyramidal system and may cause severe arrhythmias if used in excessive doses.